13F HOLDINGS REPORT
Saturn V Capital Management LLC
Quarter ended Q2 2025 · Filed August 13, 2025 · Accession 0001964437-25-000008
Total Value
$246.8M
Positions
24
Other Managers
0
Confidential Omitted
No
Holdings (24)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | JAZZ PHARMACEUTICALS PLC | JAZZ | 206,952 | $22.0M | 8.90% |
| 2 | DISC MEDICINE INC | IRON | 396,115 | $21.0M | 8.50% |
| 3 | AMYLYX PHARMACEUTICALS INC | AMLX | 3,260,570 | $20.9M | 8.47% |
| 4 | VAXCYTE INC | PCVX | 544,221 | $17.7M | 7.17% |
| 5 | COGENT BIOSCIENCES INC | COGT | 2,297,524 | $16.5M | 6.69% |
| 6 | CELCUITY INC | CELC | 1,185,520 | $15.8M | 6.41% |
| 7 | CG ONCOLOGY INC | CGON | 586,647 | $15.3M | 6.18% |
| 8 | XENON PHARMACEUTICALS INC | XENE | 468,364 | $14.7M | 5.94% |
| 9 | DYNE THERAPEUTICS INC | DYN | 1,455,429 | $13.9M | 5.62% |
| 10 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 290,784 | $13.7M | 5.56% |
| 11 | MERUS N V | N5749R100 | 224,260 | $11.8M | 4.78% |
| 12 | CENTESSA PHARMACEUTICALS PLC | CNTA | 793,327 | $10.4M | 4.22% |
| 13 | LENZ THERAPEUTICS INC | LENZ | 342,312 | $10.0M | 4.07% |
| 14 | NEUROCRINE BIOSCIENCES INC | NBIX | 58,181 | $7.3M | 2.96% |
| 15 | OCULAR THERAPEUTIX INC | OCUL | 728,576 | $6.8M | 2.74% |
| 16 | ASCENDIS PHARMA A/S | ASND | 38,191 | $6.6M | 2.67% |
| 17 | ARGENX SE | ARGX | 10,285 | $5.7M | 2.30% |
| 18 | ABIVAX SA | AAVXF | 622,479 | $4.8M | 1.93% |
| 19 | SYNDAX PHARMACEUTICALS INC | SNDX | 500,551 | $4.7M | 1.90% |
| 20 | NEWAMSTERDAM PHARMA COMPANY | NAMSW | 220,695 | $4.0M | 1.62% |
| 21 | CONTINEUM THERAPEUTICS INC | CTNM | 319,348 | $1.3M | 0.51% |
| 22 | REPLIMUNE GROUP INC | REPL | 128,917 | $1.2M | 0.49% |
| 23 | KALVISTA PHARMACEUTICALS INC | KALV | 62,793 | $709,875 | 0.29% |
| 24 | SILENCE THERAPEUTICS PLC | SLNCF | 34,737 | $201,475 | 0.08% |